NCCN Guidelines® vs Residipok

The National Comprehensive Cancer Network® (NCCN®), is pleased to present the Virtual Library of NCCN Guidelines® app formatted for iPhone & iPad. This easy-to-use and convenient format will further assist health care professionals in their implementation of the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®), thus improving the quality and effectiveness of care provided to patients with cancer. NCCN is a not-for-profit alliance of leading cancer centers devoted to patient care, research, and education. NCCN is dedicated to improving and facilitating quality, effective, efficient, and accessible cancer care so patients can live better lives. Through the leadership and expertise of clinical professionals at NCCN Member Institutions, NCCN develops resources that present valuable information to the numerous stakeholders in the health care delivery system. By defining and advancing high-quality cancer care, NCCN promotes the importance of continuous quality improvement and recognizes the significance of creating clinical practice guidelines appropriate for use by patients, clinicians, and other health care decision-makers around the world. Over the past 25 years, NCCN has developed an integrated suite of tools to improve the quality of cancer care. The NCCN Guidelines® document evidence-based, consensus-driven management to ensure that all patients receive preventive, diagnostic, treatment, and supportive services that are most likely to lead to optimal outcomes. The NCCN Guidelines are a comprehensive set of guidelines detailing the sequential management decisions and interventions that apply to 97 percent of cancer cases in the United States. In addition, separate guidelines relate to major prevention and screening topics and another set of pathways focuses on the major supportive care areas. The NCCN Guidelines provide recommendations based on the best evidence available at the time they are derived. Because new data are published continuously, it is essential that the NCCN Guidelines also be continuously updated and revised to reflect new data and new clinical information. The intent of the NCCN Guidelines is to assist in the decision-making process of individuals involved in cancer care—including physicians, nurses, pharmacists, payers, patients and their families—with the ultimate goal of improving patient care and outcomes. The NCCN Guidelines provide recommendations for appropriate care for most but not all patients; however, individual patient circumstances must be considered when applying these recommendations. Visit NCCN.org to learn more about the NCCN Guidelines as well as other NCCN Content.

Residipok is a pocket reference for licensed healthcare professionals, trainees, and medical students of accredited health-professions programs. TWO MODULES (v0.4) • MIC Lookup Choose a bacterium and an antibiotic to see the EUCAST v16.0 (2026) Clinical Breakpoint thresholds — S, I, R bands by clinical context (systemic, meningitis, urinary, high-dose). Enter an MIC value to categorise it. Special states clearly labelled when no breakpoint is published or the organism is intrinsically resistant. Built especially for pan-resistance scenarios where every threshold matters. • ESC Guideline Reference Structured Class / Level of Evidence summaries of recent ESC cardiology guidelines, covering acute coronary syndromes, heart failure, atrial fibrillation, hypertension, endocarditis, cardiomyopathies, valvular disease, pulmonary hypertension and embolism, peripheral arterial disease, dyslipidaemia, prevention, pregnancy, syncope, supraventricular tachycardia, and more. Each recommendation card links back to the original guideline on escardio.org. IMPORTANT — REFERENCE ONLY • Residipok is NOT a medical device. • It does NOT diagnose, treat, cure, or prevent disease. • It is NOT a substitute for clinical judgement or for the original published guideline / breakpoint table. • Always verify against the current EUCAST table and the latest ESC document before clinical reporting. Requires confirmation of HCP / trainee status on first launch. Sign-in by email, Apple, or Google. Sources: EUCAST Clinical Breakpoint Tables v16.0 (2026); European Society of Cardiology Clinical Practice Guidelines (2018–2024).